Abbott receives CE mark for the TactiFlex duo ablation catheter for the treatment of patients with abnormal heart rhythms

Abbott has recently announced that it has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with atrial fibrillation. Following the new approval, the first successful commercial cases using TactiFlex Duo in the European Union were completed this week.

Note that Abbott’s TactiFlex Duo Catheter is the latest advancement in the company’s pulsed field ablation technology portfolio. An effective cardiac ablation which is a minimally invasive procedure to stop an irregular heart rhythm, relies on the quality of the scars created by a catheter to stop the source of an arrhythmia. TactiFlex Duo is designed to deliver tailored therapy lesions in two ways: radiofrequency energy and pulsed field ablation energy.

“TactiFlex Duo’s most unique feature is its dual options that allow physicians to seamlessly switch treatment during a procedure based on the patient’s personalized needs and anatomy,” said Prof. Isabel Deisenhofer, M.D., head of the department of Electrophysiology at the German Heart Center Munich in Germany, and one of the first physicians to use TactiFlex Duo following CE Mark approval. “For patients who do not respond to medication and other traditional treatments, a successful cardiac ablation is critical as it can reduce the risk of recurrence of AFib and provide long-lasting relief.”

 

---

---

Related Topics and Keywords

Abbott, Ablation Catheter, TactiFlex